Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 SARA ABOOBACKER Strides Pharma Science Ltd - 532531 - Intimation Pursuant To Regulation 31A Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations').
Request received for reclassification of shareholding from 'Promoter/ Promoter Group' to 'Public' Category' Strides Pharma Science Ltd - 532531 - Strides Announces Completion Of Transaction To Acquire Manufacturing Facility In The US Along With Basket Of Andas From Endo International Plc
This has reference to our earlier Press Release of August 6, 2021 titled 'Strides inks definitive agreement with Endo to acquire its manufacturing facility in the US along with basket of ANDAs'. With reference to above, we wish to inform you that the transaction has now achieved closure. This is for your information and records. Strides Pharma Science Ltd - 532531 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 154496 Name of the Signatory :- Manjula RamamurthyDesignation :- Company Secretary and Compliance Officer Strides Pharma Science Ltd - 532531 - Shareholding for the Period Ended September 30, 2021
Strides Pharma Science Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here Strides Pharma Science Ltd - 532531 - Intimation Pursuant To Regulation 31A Of The Sebl (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')
With reference to the above, we wish to inform you that both the Stock Exchanges i.e., BSE Limited and The National Stock Exchange of India Limited have approved the reclassification of SeQuent Scientific Limited from 'Promoter Group' to 'Public' Category on October 11, 2021. Copy of approval email/ letter received from BSE and NSE in this matter is enclosed for your reference. Request you to kindly take the same on record and oblige. Strides Pharma Science Ltd - 532531 - Intimation Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 Regarding Termination Of Shareholders' Agreement Of May 16, 2016.
Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 regarding termination of Shareholders' Agreement of May 16, 2016. Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 PURUSHOTHAMAN RAJA GOPAL MUKESH MIGLANI Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 08, 2021 for Pronomz Ventures LLP Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 MATHEWS DANIEL